3696 — Insilico Medicine Cayman TopCo Income Statement
0.000.00%
Last trade - 00:00- HK$32.77bn
- HK$31.15bn
- $56.24m
Annual income statement for Insilico Medicine Cayman TopCo, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | PRESS |
| Standards: | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 30.1 | 51.2 | 85.8 | 56.2 |
| Cost of Revenue | ||||
| Gross Profit | 19.1 | 38.6 | 77.6 | 45.8 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Unusual Expense / Income | ||||
| Other Operating Expenses | ||||
| Total Operating Expenses | 114 | 137 | 112 | 111 |
| Operating Profit | -83.4 | -85.5 | -25.9 | -54.6 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -222 | -212 | -16.9 | -352 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -222 | -212 | -17.1 | -352 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -222 | -212 | -17.1 | -352 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -222 | -212 | -17.1 | -352 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.395 | -0.371 | -0.03 | -0.626 |